APRE

SEC source: 0001104659-25-031991 · tm2511518-1_4seq1.xml · nonDerivative · entry 2

Gilad Oren · CIK 0001929300 · Director · President/CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,620

SEC source: 0001104659-25-031991 · tm2511518-1_4seq1.xml · nonDerivative · entry 1

Gilad Oren · CIK 0001929300 · Director · President/CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 343,123

SEC source: 0001104659-25-029914 · tm2510809-1_4seq1.xml · derivative · entry 4

Gilad Oren · CIK 0001929300 · Director · President/CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,900

Underlying: Common Stock · 26,900 shares

Expires 2035-03-28

F3 · derivative.exercise_date: Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-25-029914 · tm2510809-1_4seq1.xml · nonDerivative · entry 1

Gilad Oren · CIK 0001929300 · Director · President/CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 340,120

F1 · shares: These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-25-029920 · tm2510809-2_4seq1.xml · derivative · entry 2

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,460

Underlying: Common Stock · 13,460 shares

Expires 2035-03-28

F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-25-029920 · tm2510809-2_4seq1.xml · nonDerivative · entry 1

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,733

F1 · shares: These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-24-111031 · tm2426748-1_4seq1.xml · nonDerivative · entry 1

Gilad Oren · CIK 0001929300 · Director · President/CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 333,395

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.91 to $3.92, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

SEC source: 0001104659-24-111548 · tm2426908-1_4seq1.xml · nonDerivative · entry 1

Duey Marc · CIK 0001925150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 233,651

F1 · kind: The Reporting Person's sale of Issuer's common stock reported herein was automatically transacted by the Reporting Person's broker as a result of an insufficient cash position in the Reporting Person's brokerage account. Further, the Reporting Person's sale of Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (i) to the extent of 190 shares, with the Reporting Person's purchase of 190 shares of the Issuer's common stock at a price of $2.5837 on October 14, 2024, and (ii) to the extent of 6,272 shares, with the Reporting Person's purchase of 30,000 shares of the Issuer's common stock at a price of $4.39 per share on October 16, 2024. The Reporting Person has agreed to pay to Issuer $1,558.05 which represents the full amount of the profit realized in connection with the short-swing transaction.

F2 · price: These shares were sold in multiple transactions on October 18, 2024, each at $4.578 per share.

SEC source: 0001104659-24-109386 · tm2426287-1_4seq1.xml · nonDerivative · entry 1

Duey Marc · CIK 0001925150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,113

SEC source: 0001104659-24-108964 · tm2426059-6_4seq1.xml · nonDerivative · entry 1

Gilad Oren · CIK 0001929300 · Director · President/CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 332,895

SEC source: 0001104659-24-108375 · tm2426059-3_4seq1.xml · nonDerivative · entry 2

Gilad Oren · CIK 0001929300 · Director · President/CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 332,645

SEC source: 0001104659-24-108963 · tm2426059-5_4seq1.xml · nonDerivative · entry 1

Duey Marc · CIK 0001925150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,113

SEC source: 0001104659-24-108377 · tm2426059-4_4seq1.xml · nonDerivative · entry 1

Seizinger Bernd R. · CIK 0001789042 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,730

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.70, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

SEC source: 0001104659-24-108962 · tm2426059-2_4seq1.xml · nonDerivative · entry 1

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,368

SEC source: 0001104659-24-108375 · tm2426059-3_4seq1.xml · nonDerivative · entry 1

Gilad Oren · CIK 0001929300 · Director · President/CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,645

SEC source: 0001104659-24-108373 · tm2426059-1_4seq1.xml · nonDerivative · entry 1

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,318

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.55 to $2.618, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

SEC source: 0001104659-24-073947 · tm2417666-5_4seq1.xml · derivative · entry 3

Pamukcu Rifat · CIK 0001929298 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,185

Underlying: Common Stock · 4,185 shares

Expires 2034-06-20

F3 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073947 · tm2417666-5_4seq1.xml · nonDerivative · entry 1

Pamukcu Rifat · CIK 0001929298 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,401

F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073932 · tm2417666-1_4seq1.xml · derivative · entry 3

Duey Marc · CIK 0001925150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,185

Underlying: Common Stock · 4,185 shares

Expires 2034-06-20

F3 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073932 · tm2417666-1_4seq1.xml · nonDerivative · entry 1

Duey Marc · CIK 0001925150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,923

F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073936 · tm2417666-2_4seq1.xml · derivative · entry 2

Grissinger Michael · CIK 0001757601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,185

Underlying: Common Stock · 4,185 shares

Expires 2034-06-20

F2 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073936 · tm2417666-2_4seq1.xml · nonDerivative · entry 1

Grissinger Michael · CIK 0001757601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,844

F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073941 · tm2417666-3_4seq1.xml · derivative · entry 2

HENNEMAN JOHN B III · CIK 0001187572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,185

Underlying: Common Stock · 4,185 shares

Expires 2034-06-20

F2 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073941 · tm2417666-3_4seq1.xml · nonDerivative · entry 1

HENNEMAN JOHN B III · CIK 0001187572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,184

F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073943 · tm2417666-4_4seq1.xml · derivative · entry 2

Peters Richard · CIK 0001697628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,185

Underlying: Common Stock · 4,185 shares

Expires 2034-06-20

F2 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073943 · tm2417666-4_4seq1.xml · nonDerivative · entry 1

Peters Richard · CIK 0001697628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,074

F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073950 · tm2417666-6_4seq1.xml · derivative · entry 2

Seizinger Bernd R. · CIK 0001789042 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,185

Underlying: Common Stock · 4,185 shares

Expires 2034-06-20

F2 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-073950 · tm2417666-6_4seq1.xml · nonDerivative · entry 1

Seizinger Bernd R. · CIK 0001789042 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,730

F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-24-056402 · tm2413094-2_4seq1.xml · derivative · entry 2

Mirza Nadeem Q. · CIK 0002021015 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,920

Underlying: Common Stock · 29,920 shares

Expires 2034-05-01

F2 · derivative.exercise_date: The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). Twenty-five percent of these options vest on May 1, 2025, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-24-056402 · tm2413094-2_4seq1.xml · nonDerivative · entry 1

Mirza Nadeem Q. · CIK 0002021015 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,730

F1 · shares: These shares were granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock, on a one-for-one basis in three (3) equal annual installments beginning on May 1, 2025, until vested in full, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-24-040642 · tm2410009-1_4seq1.xml · derivative · entry 4

Gilad Oren · CIK 0001929300 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,900

Underlying: Common Stock · 26,900 shares

Expires 2024-03-28

F3 · derivative.exercise_date: Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-24-040642 · tm2410009-1_4seq1.xml · nonDerivative · entry 1

Gilad Oren · CIK 0001929300 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,495

F1 · shares: These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-24-040645 · tm2410009-2_4seq1.xml · derivative · entry 2

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,460

Underlying: Common Stock · 13,460 shares

Expires 2024-03-28

F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-24-040645 · tm2410009-2_4seq1.xml · nonDerivative · entry 1

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,868

F1 · shares: These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

SEC source: 0001104659-24-034670 · tm248935-1_4seq1.xml · derivative · entry 3

Gilad Oren · CIK 0001929300 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires not disclosed

F4 · derivative.exercise_price: The exercise price of the Tranche B Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.

F6 · price: The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.

F5 · derivative.expiration_date: Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.

SEC source: 0001104659-24-034670 · tm248935-1_4seq1.xml · derivative · entry 2

Gilad Oren · CIK 0001929300 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The exercise price of the Tranche A Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.

F3 · price: The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.

F2 · derivative.expiration_date: Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.

SEC source: 0001104659-24-034670 · tm248935-1_4seq1.xml · nonDerivative · entry 1

Gilad Oren · CIK 0001929300 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,770

SEC source: 0001104659-24-034671 · tm248935-2_4seq1.xml · derivative · entry 3

HENNEMAN JOHN B III · CIK 0001187572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,430

Underlying: Common Stock · 3,430 shares

Expires not disclosed

F4 · derivative.exercise_price: The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.

F6 · price: The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.

F5 · derivative.expiration_date: Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.

SEC source: 0001104659-24-034671 · tm248935-2_4seq1.xml · derivative · entry 2

HENNEMAN JOHN B III · CIK 0001187572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,430

Underlying: Common Stock · 3,430 shares

Expires not disclosed

F1 · derivative.exercise_price: The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.

F3 · price: The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.

F2 · derivative.expiration_date: Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.

SEC source: 0001104659-24-034671 · tm248935-2_4seq1.xml · nonDerivative · entry 1

HENNEMAN JOHN B III · CIK 0001187572 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,139

SEC source: 0001104659-24-034673 · tm248935-4_4seq1.xml · derivative · entry 3

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 505

Underlying: Common Stock · 505 shares

Expires not disclosed

F4 · derivative.exercise_price: The exercise price of the Tranche B Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.

F6 · price: The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.

F5 · derivative.expiration_date: Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.

SEC source: 0001104659-24-034673 · tm248935-4_4seq1.xml · derivative · entry 2

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 505

Underlying: Common Stock · 505 shares

Expires not disclosed

F1 · derivative.exercise_price: The exercise price of the Tranche A Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.

F3 · price: The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.

F2 · derivative.expiration_date: Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.

SEC source: 0001104659-24-034673 · tm248935-4_4seq1.xml · nonDerivative · entry 1

Hamill John P. · CIK 0001716213 · SrVP/CFO/Prin Fin & Acct Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,503

SEC source: 0001104659-24-034672 · tm248935-3_4seq1.xml · derivative · entry 3

Seizinger Bernd R. · CIK 0001789042 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,430

Underlying: Common Stock · 3,430 shares

Expires not disclosed

F4 · derivative.exercise_price: The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.

F6 · price: The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.

F5 · derivative.expiration_date: Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.

SEC source: 0001104659-24-034672 · tm248935-3_4seq1.xml · derivative · entry 2

Seizinger Bernd R. · CIK 0001789042 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,430

Underlying: Common Stock · 3,430 shares

Expires not disclosed

F1 · derivative.exercise_price: The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.

F3 · price: The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.

F2 · derivative.expiration_date: Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.

SEC source: 0001104659-24-034672 · tm248935-3_4seq1.xml · nonDerivative · entry 1

Seizinger Bernd R. · CIK 0001789042 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,685

SEC source: 0001104659-23-095021 · tm2324788-8_4seq1.xml · derivative · entry 6

Pamukcu Rifat · CIK 0001929298 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires 2033-08-23

F5 · derivative.exercise_date: The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-23-095021 · tm2324788-8_4seq1.xml · nonDerivative · entry 2

Pamukcu Rifat · CIK 0001929298 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,356

F2 · shares: These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

F3 · balance_after: Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023

SEC source: 0001104659-23-095017 · tm2324788-4_4seq1.xml · derivative · entry 6

Duey Marc · CIK 0001925150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires 2033-08-23

F5 · derivative.exercise_date: The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

SEC source: 0001104659-23-095017 · tm2324788-4_4seq1.xml · nonDerivative · entry 2

Duey Marc · CIK 0001925150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,878

F1 · shares: These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

F2 · balance_after: Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023